drugset / Trial / NCT03072667

Omegaven for Compassionate Use in the Treatment of Parenteral Nutrition-Associated Liver Disease

NCT03072667

Expanded access Approved for marketing Catherine Cibulskis, MD St. Louis University · collab

Summary

This is a compassionate use protocol of an investigational new drug (IND). The overall purpose of the treatment is to offer alternative treatment to children who developed parenteral nutrition-associated liver disease (PNALD) and have not responded positively to currently available medical therapies. PNALD develops in newborns dependent on parenteral nutrition (PN) and are unable to tolerate adequate enteral feedings to support fluid and nutritional fluids; although PN is necessary and life sustaining, it can result in severe liver disease.

Timeline

Start
Primary completion
Completion

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Omegaven Other / unclassified 1 g/kg Intravenous